AURLUMYN

Growth

iloprost

NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
12

Mechanism of Action

2 . Iloprost is a vasodilator and inhibits platelet aggregation.

Pharmacologic Class:

Prostacycline

Clinical Trials (5)

NCT03293407N/ACompleted

Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

Started Feb 2018
31 enrolled
Hypertension, Pulmonary
NCT02826252N/ACompleted

Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)

Started Sep 2016
64 enrolled
Hypertension, Pulmonary
NCT02482402Phase 2Withdrawn

Iloprost for Bridging to Heart Transplantation in PH

Started Feb 2015
0
Chronic Left Ventricular FailurePulmonary Hypertension
NCT01894035N/ACompleted

Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation

Started Sep 2013
13 enrolled
Pulmonary Hypertension
NCT01469169Phase 3Completed

Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study

Started Jun 2012
27 enrolled
Hypertension, Pulmonary

Loss of Exclusivity

LOE Date
Jul 18, 2044
223 months away
Patent Expiry
Jul 18, 2044
Exclusivity Expiry
Feb 13, 2031

Patent Records (2)

Patent #ExpiryTypeUse Code
12409184
Aug 6, 2041
Product
12409183
Jul 18, 2044
U-4263